Background: Pulmonary arterial hypertension (PH) is a progressive disease with limited therapeutic options, ultimately leading to right heart failure and death. Recent findings indicate the role of the Warburg effect (aerobic glycolysis) in the development of PH. However, the effect of the glycolysis inhibitor 3-bromopyruvate (3-BrPA) on the pathogenesis of PH has not been well investigated. This study aimed to determine whether 3-BrPA inhibits PH and its possible mechanism. Methods: PH was induced in adult Sprague-Dawley rats by a single intraperitoneal injection of monocrotaline (MCT). 3-BrPA, or phosphate-buffered saline (PBS) was administered via intraperitoneal injection every other day from the first day of MCT-injection to 4 weeks of follow-up, and indices such as right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI), pulmonary arteriolar remodeling indicated by percent media thickness (% MT), lactate levels and glucose consumption, were evaluated. Pulmonary arteriolar remodeling and right ventricular hypertrophy were observed in hematoxylin-eosin-stained lung sections. Western blotting, immunohistochemistry, and/or immunofluorescence analyses were used to measure the expression of relevant proteins. A cytochrome C release apoptosis assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling staining were used to measure cell apoptosis. Results: MCT-induced PH showed a significant increase in glucose consumption (0 vs. 4 weeks: 0.87 ± 0.23 vs. 2.94 ± 0.47, P = 0.0042) and lactate production (0 vs. 4 weeks: 4.19 ± 0.34 vs. 8.06 ± 0.67, P = 0.0004). Treatment with 3-BrPA resulted in a concomitant reduction in glucose consumption (1.10 ± 0.35 vs. 3.25 ± 0.47, P = 0.0063), lactate production (5.09 ± 0.55 vs. 8.06 ± 0.67, P = 0.0065), MCT-induced increase in RVSP (39.70 ± 2.94 vs. 58.85 ± 2.32, P = 0.0004), pulmonary vascular remodeling (% MT, 43.45% ± 1.41% vs. 63.66% ± 1.78%, P < 0.0001), and right ventricular hypertrophy (RVHI, 38.57% ± 2.69% vs. 62.61% ± 1.57%, P < 0.0001) when compared with those of the PBS-treated group. 3-BrPA, a hexokinase 2 inhibitor, exerted its beneficial effect on PH by decreasing aerobic glycolysis and was also associated with inhibiting the expression of glucose transporter protein-1, inducing apoptosis, and suppressing inflammation. Conclusions: 3-BrPA might have a potential beneficial effect on the PH treatment.
Introduction
Pulmonary arterial hypertension (PH) is a progressive and life-threatening disease characterized by pulmonary vasoconstriction and remodeling, ultimately leading to right heart failure and death. Clinically, limited treatments mainly focus on vasodilatation to alleviate symptoms and improve quality of life. [1] More recent advances are based on targeting pulmonary vascular remodeling to mainly pyruvate to lactate acid despite the presence of abundant oxygen. [5] The Warburg effect serves as a critical mechanism in the development of PH by largely driving cellular hyperproliferation and apoptosis resistance. [6] Recent studies have shown that the glycolysis inhibitor 3bromopyruvic acid (3-BrPA) is a promising anti-cancer compound capable of inducing rapid cell death in numerous cancer cells with limited cytotoxic effects against normal cells by inhibiting the activities of metabolic enzymes such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hexokinase 2 (HK-2), succinic dehydrogenase. [7] [8] [9] In addition, 3-BrPA is able to dissociate and inhibit mitochondria-bound HK-2 function, thereby allowing proapoptotic molecules to promote the release of Cyto C into the cytosol and induce caspase-3 (Casp 3) activation. [10] It has been reported that 3-BrPA could reverse hypoxia-induced PH by inhibiting glycolysis, [11] but until now, the effect of 3-BrPA on the development of monocrotaline (MCT)-induced PH has not been well studied.
In the present study, we hypothesized that treatment with 3-BrPA may be effective in the MCT-induced PH rat model. Therefore, this study was designed to evaluate the level of aerobic glycolysis and the effect of 3-BrPA in MCTinduced PH and to explore the mechanisms of the potential beneficial effect of 3-BrPA on PH treatment, with the aim of finding a novel strategy for PH treatment.
Methods

Animals
Adult male Sprague-Dawley rats weighing 250 to 300 g were purchased from the Vital River Laboratory Animal Technology Company of Beijing in China and maintained in a temperature-controlled room with a 12-12 h lightdark cycle. All animal care and experiments were approved by the Institutional Animal Care and Use Committee of Capital Medical University and performed in accordance with the Management of Laboratory Animals published by the Ministry of Science and Technology of the People's Republic of China.
The PH model was induced by a single intraperitoneal injection (60 mg/kg, i.p.) of MCT (Catalog No. C2401; Sigma-Aldrich, Saint Louis, USA). Control animals were given a single intraperitoneal injection of the same volume of 0.9% NaCl. For the 3-BrPA (Catalog No. 16490; Sigma-Aldrich) treatment, MCT-induced PH rats were injected intraperitoneally with either 3-BrPA (2 mmol/L, i.p.) [12] or the same volume of phosphate-buffered saline (PBS) every other day beginning on the day of MCT injection to 4 weeks of follow-up.
Measurement of the right ventricular systolic pressure
The rats were anesthetized with 2% sodium pentobarbital (45 mg/kg, i.p.). A catheter filled with heparinized saline was inserted into the right ventricle (RV) via the jugular vein to measure right ventricular systolic pressure (RVSP). The RVSP was then recorded by a PowerLab data acquisition system (AD Instruments, Sydney, Australia) and digitized by LabChart software (AD Instruments). The average RV pressure was measured during systole to determine the individual RVSP.
Measurements of glucose and lactate concentration
Before the experiments and after hemodynamic measurement, the serum of the rats was collected. Then, the rats were euthanized by exsanguination. The glucose and lactate levels were detected using a lactate-and glucosemeasuring instrument (EKF Diagnostics, Barleben, Germany). Glucose levels were detected at 0 and 4 weeks, and glucose consumption = (glucose level at 0 week) À (glucose level at 4 weeks).
Measurement of right ventricular hypertrophy
Heart tissue was removed. The RV free wall was dissected from the left ventricle (LV) and ventricular septum (S). The RV hypertrophy index (RVHI) was calculated by the wet weight ratio of the RV to the LV plus S using the formula: RV/(LV + S) Â 100%. The ratio of RV weight to body weight (BW) was also examined.
Cardiomyocyte cross-sectional diameter was determined in the RV and LV as measures of cardiac ventricular tissue remodeling. Four-micron sections of the RV and LV were stained with hematoxylin and eosin (H&E), and the diameter of individual cardiomyocytes in histological sections of the left and right ventricular walls was measured. Microscopic images were analyzed in a blinded manner using a Nikon microscope digital camera system and its image analysis program (Nikon, Tokyo, Japan).
Lung tissue preparation and morphometric analysis
The left lungs embedded in paraffin were serially sectioned at a thickness of 4-mm for standard H&E staining, immunohistochemistry, and immunofluorescence. Pulmonary vessels with external diameters smaller than 150 mm were selected. Medial thickness was determined as follows: percent medial thickness (% MT) = (circumference ext /p À circumference int /p)/(circumference ext /p) Â 100%. The circumference ext and circumference int were demarcated by the external and internal elastic lamina, respectively. Images of pulmonary vessels were captured with a Nikon microscope digital camera system, and circumferences were measured with the image analysis program.
Immunohistochemical analysis
Immunoreactivity of HK-2 was detected in paraffinembedded human lung sections using a rabbit anti-human HK-2 antibody (1:500 dilution, Catalog No. ab209847, Abcam, UK). Positive signals were visualized using an horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:200 dilution, Catalog No. 8114, CST, Danvers, MA, USA). The positive cells were developed by diaminobenzidine (DAB) reagent, and the nuclei were stained with hematoxylin.
Assessment of macrophage infiltration
Staining for CD68 (Sigma-Aldrich) by using standard immunofluorescence protocols was performed to quantify Chinese Medical Journal 2020;133 (1) www.cmj.org the degree of macrophage lung infiltration. Briefly, CD68 expression levels were detected in paraffin-embedded lung sections using the anti-CD68 antibody ( 
TUNEL staining
The terminal deoxynucleotidyl transferase-mediated dUTPbiotin nick end labeling (TUNEL) assay was performed with in situ cell death detection kits (Catalog No. C1091; Beyotime Biotechnology, Beijing, China) according to the manufacturer's instructions. Briefly, the slides were rinsed twice with PBS. The samples were treated with proteinase K solution for 30 min at 37°C. The slides were rinsed twice with PBS. The area around each sample was dried, and 50 mL TUNEL reaction mixture was added to the sample and incubated for 60 min at 37°C in a humidified atmosphere in the dark. The slides were rinsed three times with PBS, 50 mL converter-peroxidase was added to the samples and incubated for 30 min at 37°C in a humidified atmosphere in the dark. The slides were rinsed three times with PBS, the positive cells were detected by diaminobenzidine reagent, and the nuclei were stained with hematoxylin.
Cytochrome c release apoptosis assay
For the rapid, sensitive and accurate detection of cytochrome c translocation from mitochondria into the cytosol during apoptosis in tissues, cell apoptosis was determined using a Cyto C release apoptosis assay kit (Catalog No. ab65311; Abcam) according to the manufacturer's instructions.
Statistical analysis
Data are expressed as the mean ± standard error. Unpaired Student's t test was used for comparisons between two groups. One-way analysis of variance with the Newman-Keuls test was used to evaluate differences between more than two groups. A value of P < 0.05 was considered statistically significant.
Results
Metabolic characteristics of MCT-induced PH rats
Four weeks after MCT injection, increases in RVSP [ Figure 1A ] (25.47 ± 1.27 vs. 52.32 ± 3.72 mmHg, 1 mmHg = 0.133 kPa), RVHI [ Figure 1B ] (28.16 ± 0.89 vs. 55.39 ± 4.06%), and pulmonary vascular remodeling [ Figure  1C ] (%  MT: 22.83% ± 0.75% vs. 61.20% ± 1.79%) were observed. The lactate and glucose levels of MCT rats were detected in serum at 2 and 4 weeks after MCT injection. Compared with the baseline concentration, the concentration of lactate was upregulated in the serum of MCT rats and significantly increased at 4 weeks after MCT injection (P < 0.001) [ Figure 1D ]. In addition, glucose consumption was significantly higher in MCT rats compared with that of the control group (P < 0.01) [ Figure 1E ]. These results indicate that MCT-induced PH increased the rate of aerobic glycolysis.
Effects of 3-BrPA on glycolysis
The typical features of aerobic glycolysis are increased glucose consumption and lactate production. To understand the effects of 3-BrPA on glycolysis in MCT-induced PH, rats were injected with MCT and received injections of PBS or 3-BrPA every other day for 4 weeks. Our data showed that 3-BrPA treatment significantly decreased the concentration of lactate (P < 0.01) compared to that in the PBS-treated rats [ Figure 2A ]. Rats treated with 3-BrPA showed significantly lower (P < 0.01) glucose consumption than that of PBS-treated rats [ Figure 2B ]. These results suggest that 3-BrPA inhibits glycolysis in PH. Figure 2C depicts the BWs, demonstrating that all rats had increased BW at 4 weeks after MCT injection (P < 0.001). In PBS-treated MCT rats, BW was reduced by 17.51% ± 0.54% (P < 0.001); in the 3-BrPA-treated group, BW was reduced by 21.39% ± 1.72% (P < 0.001) at 4 weeks after MCT injection compared with that of the control group.
Effects of 3-BrPA on BW and right ventricular systolic pressure
RVSP is used as an indicator of pulmonary arterial systolic pressure. MCT injection led to PH characterized by a significant increase in RVSP to 58.85 ± 2.32 mmHg 4 weeks after MCT injection compared with that of the control group (26.38 ± 0.67 mmHg) (P < 0.001). Treatment with 3-BrPA significantly reduced the MCT-induced increase in RVSP to 39.70 ± 2.94 mmHg compared with that of the PBS-treated MCT rats (P < 0.001) [ Figure 2D ]. Taken together, these results show that MCT injection effectively induces PH in rats and is distinctly attenuated by 3-BrPA.
Effects of 3-BrPA on pulmonary arteriolar remodeling
Progressive medial thickening is a major characteristic in PH. To investigate the effects of 3-BrPA on MCT-induced remodeling of pulmonary arterioles, H&E staining of lungs from control, PBS-treated and 3-BrPA-treated MCT rats was used for morphometric analysis. Representative specimens showed that the medial thickness of peripheral pulmonary vessels was evidently increased in PBS-treated MCT rats. However, these changes appeared to be ameliorated in 3-BrPA-treated MCT rats [ Figure 2E ].
Quantitative analysis of %MT is used to evaluate the medial thickening of pulmonary arterioles. As shown in Figure 2F , the %MT of peripheral pulmonary vessels showed enhanced medial wall thickness from 26.39% ± 1.17% in the control group to 63.66% ± 1.78% in the PBS-treated group in intra-acinar vessels sized smaller than 150 mm (P < 0.001). In the 3-BrPA-treated group, the increase in medial wall thickness was significantly decreased to 43.45% ± 1.41% compared with that of the PBS-treated MCT rats (P < 0.001). These results demonstrate the anti-remodeling impact of 3-BrPA on the pulmonary vasculature.
Effects of 3-BrPA on right ventricular hypertrophy
The presence of right ventricular hypertrophy is a hallmark of end-stage PH. The ratios of RV/BW and RVHI express the degree of RV hypertrophy. Compared to the ratio in the control group, the RV/BW ratio increased significantly by 1.13 ± 0.18 fold (P < 0.001) in PBS-treated MCT rats at 4 weeks. 3-BrPA treatment reduced the RV/BW ratio by 29.90% ± 6.03% (P < 0.01) at 4 weeks after MCT injection [ Figure 3A ]. RVHI in PBS-treated MCT rats also demonstrated a marked elevation of 62.61% ± 1.57%, compared with that of the control group (28.25% ± 0.48%) (P < 0.001) [ Figure 3B ]. A prominent reduction in RVHI was observed in rats treated with 3-BrPA (38.57% ± 2.69%) compared with that of the PBS-treated MCT rats (P < 0.001).
Ventricular hypertrophy was also evaluated by measuring the diameters of cardiomyocytes. Figure 3C depicted representative H&E staining of heart tissue for control PBS-treated and 3-BrPA-treated MCT-Rats of heart tissues. The diameters of cardiomyocytes were further measured as a parameter of ventricular hypertrophy. Cardiomyocyte diameter was enhanced from 21.83 ± 0.21 to 40.07 ± 0.49 mm with PBS treatment and significantly reduced to 29.26 ± 0.40 mm with 3-BrPA treatment in MCT rats [ Figure 3D ]. The cardiomyocyte diameter remained largely unchanged in the LV [ Figure 3E ]. These data demonstrate that 3-BrPA can effectively protect against the MCT-triggered hypertrophy of individual cardiomyocytes in the RV.
Effects of 3-BrPA on the expression of HK-2 and glucose transporter protein-1 in MCT-induced PH rats
HK-2 is the key mediator of glucose metabolism and catalyzes the first rate-limiting step during aerobic glycolysis. Therefore, the expression of HK-2 in the lungs of MCT rats was observed by Western blotting Chinese Medical Journal 2020;133(1) www.cmj.org analysis at 2 and 4 weeks after MCT injection. Compared with the baseline expression, the expression of HK-2 was upregulated in the lungs of MCT rats and significantly increased at 4 weeks after MCT injection (P < 0.05) [ Figure 4A ]. These results suggest that MCT-induced PH is associated with HK-2 upregulation. It has been reported that 3-BrPA is an inhibitor of HK-2, and the effects of 3-BrPA on the expression of HK-2 in MCTinduced PH rats were examined by Western blotting and immunohistochemical analysis. The results showed that after 3-BrPA injection in MCT rats, the expression of HK-2 in rat lungs was downregulated compared to that of PBS-treated MCT rats [ Figure 4B and 4C]. The results of the immunohistochemical analysis showed that HK-2 stained mainly in the perivascular area, and then we investigated the localization of HK-2 by co-staining HK-2 and smooth muscle cell markers. As shown in Figure 5 , the immunoreactivity of HK-2 significantly increased in the lung tissue of MCT rats, and the positive signals were predominantly found in the perivascular area, while 3-BrPA reversed this effect.
Aerobic glycolysis results from increased glucose uptake, glucose transporter protein-1 (GLUT1) plays a critical role in glucose uptake, and increased expression of GLUTs is responsible for aerobic glycolysis. As shown in Figure 6 , MCT induced the expression of GLUT1, while 3-BrPA reversed this effect.
Effects of 3-BrPA on apoptosis
Several lines of evidence suggest that 3-BrPA induces apoptosis in cancer cells. [13, 14] The effects of 3-BrPA on apoptosis in MCT rats were further examined by measuring the changes in the expression of apoptosisassociated proteins. The amount of cleaved Casp 3 protein expression was increased in the 3-BrPA treatment MCT rats [ Figure 7A ]. Furthermore, we observed decreased Cyto C in mitochondria [ Figure 7B ] and increased the release of Cyto C into the cytoplasm in the 3-BrPA-treated MCT rats compared to those of PBS-treated MCT rats [ Figure 7C ]. These results show that 3-BrPA leads to the activation of the mitochondrial apoptotic signaling pathway.
A TUNEL assay was used to further investigate the apoptosis effect of 3-BrPA, as shown in Figure 7D . TUNEL-positive cells in the lung tissue of 3-BrPA-treated MCT rats were significantly increased compared with those of control and PBS-treated MCT rats.
Effects of 3-BrPA on inflammatory infiltration
Inflammatory infiltration and macrophage invasion have been shown to represent key features in PH. [15] We thus evaluated the macrophage content in the lungs of all three animal groups [ Figure 8 ]. The number of macrophages and CD68-positive cells in the lungs of PBS-treated MCT rats was significantly higher than that in the control group. In Chinese Medical Journal 2020;133(1) www.cmj.org contrast, 3-BrPA treatment of MCT rats showed a reduction compared to that of PBS-treated MCT rats. Thus, in addition to beneficial hemodynamic and structural changes in the lung and heart by 3-BrPA, inflammatory infiltration was also effectively reduced. To investigate the localization of macrophages in the lung tissue, co-staining of CD68 and smooth muscle cell markers was performed and showed that MCT-induced macrophage infiltration was mainly located in the perivascular area [ Figure 9 ] and that 3-BrPA reversed MCT-induced macrophage infiltration.
Discussion
In this study, we demonstrated a significantly increased rate of aerobic glycolysis in the MCT-induced PH rats. Treatment with 3-BrPA, a glycolysis inhibitor, was effective in reducing right ventricular systolic pressure, pulmonary arteriolar remodeling, and right ventricular hypertrophy via inhibiting HK-2, activating the apoptosis pathway and suppressing PH-associated lung inflammation, indicating that 3-BrPA has the potential to be an attractive therapeutic strategy in treating PH.
PH represents a fatal disease with limited therapeutic options targeting the nitric oxide, prostacyclin, and endothelin pathways, and the current life expectancy is comparable to that of metastatic cancer. [16] In recent decades, many researchers have found that PH and cancer share similar poor prognoses and major pathophysiological mechanisms, including increased cell proliferation, apoptosis resistance, and metabolic shift. [17] Interestingly, studies have reported that the tissue of PH patients and experimental PH exhibit the Warburg effect, which indicates that the pathogenesis of PH is similar to that of cancer biology. [18] Lactate production and glucose consumption, typical features of the Warburg effect, and HK-2, the essential enzyme for aerobic glycolysis, were reported to be increased in pulmonary arterial smooth muscle cells of chronic thromboembolic pulmonary hypertension patients. [3] Consistent with our previous findings, the present study showed that lactate production, glucose consumption, and expression of HK-2 were also increased in MCT rats.
HKs catalyzes the first irreversible step in glycolysis. There are four major isoforms (HK-1, HK-2, HK-3, and HK-4) Chinese Medical Journal 2020;133(1) www.cmj.org characterized in mammalian tissue. [19] Among these different HKs, HK-2 is often overexpressed in many tumors. The upregulated HK-2 binds to the mitochondrial VDACs and promotes tumor cell proliferation and survival by inhibiting Cyto C release and escaping from apoptosis. [20] These results suggest that HK-2 has a potential role in the development of PH. However, the mechanism was not identified in our study. Hypoxia-inducible factor-1a (HIF-1a) activation plays an important role in cellular metabolism. [6] In addition, the proximal promoter of HK-2 contains binding sites for HIF-1a. [21] Therefore, we hypothesize that HIF-1a transcriptionally upregulates glycolysis via increased expression of HK-2 in MCT rats.
3-BrPA has been described recently as a remarkably effective anti-cancer drug by rapidly inhibiting tumor cell growth in tissue culture, eradicating cancers in animals, and preventing metastasis. [7] It has been reported that 3-BrPA inhibits the energy-obtaining process of tumor cells by inhibiting the activities of metabolic enzymes [8, 9] and regulating the expression of substance transport carriers and signaling pathways involved in cell division, autophagy, and apoptosis. [22, 23] Among these, 3-BrPA is also used as a typical inhibitor of HK-2 via alkylation. [10, 23, 24] In this study, we showed that treatment with 3-BrPA was effective in reducing aerobic glycolysis, right ventricular systolic pressure, pulmonary arteriolar remodeling, and right ventricular hypertrophy in MCT rats. A previous study demonstrated that 3-BrPA inhibited glycolysis as well as mitochondria-bound HK-2 and consequently led to apoptosis in cancer cells. [25] In the current study, we demonstrated that 3-BrPA downregulated the expression of HK-2 and promoted apoptosis in MCT-PH rats through increased release of proapoptotic mediators such as Cyto C and cleaved Casp 3. Therefore, these data suggest that 3-BrPA is effective against MCT-PH via downregulating HK-2 and activating mitochondrial apoptosis.
PH is characterized by increased production of proinflammatory cytokines and perivascular inflammatory features. [26] Finally, we evaluated the potential influence of 3-BrPA on pulmonary inflammation by determining the abundance of macrophages in the lung. MCT rats were associated with a highly elevated content of cells that were positive for the macrophage biomarker CD68, and when MCT rats were treated with 3-BrPA, the number of CD68positive cells was reduced. Thus, 3-BrPA also effectively reduced inflammatory infiltration in MCT rats.
Our results provide evidence that 3-BrPA, a glycolysis inhibitor, is effective in reducing multiple pathological processes in MCT-induced PH, including aerobic glycolysis, right ventricular systolic pressure, pulmonary arteriolar remodeling, and right ventricular hypertrophy. These data also demonstrate that 3-BrPA exerts its beneficial effect on PH by targeting HK-2 in a manner that was associated with inducing apoptosis and suppressing inflammation. In conclusion, our findings suggest that 3-BrPA might has a potential beneficial effect on the PH treatment. 
